Treat Stroke to Target "TST"


Phase N/A Results N/A

Eligibility Criteria

Inclusion Criteria

- • Recent (less than 3 months) ischemic stroke
- As soon as possible after the event, once the neurologic deficit is stabilized (investigator judgment)
- These ischemic strokes include TIA with ischemic lesion documented by CT or MRI
• Or recent TIA (less than 15 days)
- without documentation of ischemic lesion on CT/MR imaging
- Must be limb weakness or aphasia lasting more than 10 min
• And documented atherosclerotic stenosis
- In carotid artery (investigator judgment) (based on the results of Duplex echography, CTA, MRA or X ray- angiography)
- Or in the aortic arch (investigator judgment) (based on TEE or CTA)
- Or in other brain artery: vertebral, basilar or other intracranial artery (based on CTA, MRA, XRA)
- Or in coronary arteries (past history of acute coronary syndrome, coronary revascularization or positive coronary angiography)
• And
- Statin treatment is indicated, following ANSM guidelines (French drug agency)
- age >18 years
- rankin score ≤ 4
- patient or a legal representative signs consent
- Patient is affiliated to social security system

Exclusion Criteria

- • Ischemic stroke/TIA du to
- arterial dissection (investigator judgment)
- Cardiac source of embolism (e.g., mitral stenosis, endomyocardial fibrosis) without documented atherosclerotic stenosis : a patient with atrial fibrillation or a past history of recent myocardial infarction or calcified aortic stenosis can be randomized if he otherwise fulfils inclusion criteria
• Symptomatic hemorrhagic stroke
- Presence of microbleeds on gradient echo imaging (T2*) is not an exclusion criteria.
- Hemorrhagic transformation of an ischemic stroke is not an exclusion criteria
- Uncontrolled hypertension (investigator judgment)
- LDL-C <100 mg/dL or patients for whom treatment intensification is impossible
- F/U impossible or bad observance anticipated.
- Co-morbid condition that may interfere with the F/U or with the evaluation of primary endpoint
- Participation to another clinical trial